Home > Insider Trading > Filing (0001181431-10-063549)

Filing Details

Accession Number:: 0001181431-10-063549
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-12-23 18:18:54
Reporting Period:: 2010-12-21

Filing Date:: 2010-12-23
Accepted Time:: 2010-12-23 18:18:54
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1382911	Orexigen Therapeutics Inc.	OREX	Pharmaceutical Preparations (2834)	651178822

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1202793	Michael Powell	C/O Sofinnova Ventures 850 Oak Grove Ave Menlo Park CA 94025		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2010-12-21	309,730	$8.38	371,184	No	4	S	Indirect	See footnote.
Common Stock	Disposition	2010-12-21	61,405	$8.38	73,376	No	4	S	Indirect	See footnote.
Common Stock	Disposition	2010-12-21	4,204	$8.38	5,101	No	4	S	Indirect	See footnote.
Common Stock	Disposition	2010-12-22	206,895	$8.30	164,289	No	4	S	Indirect	See footnote.
Common Stock	Disposition	2010-12-22	41,018	$8.30	32,358	No	4	S	Indirect	See footnote.
Common Stock	Disposition	2010-12-22	2,808	$8.30	2,293	No	4	S	Indirect	See footnote.
Common Stock	Disposition	2010-12-23	164,289	$8.09	0	No	4	S	Indirect	See footnote.
Common Stock	Disposition	2010-12-23	32,358	$8.09	0	No	4	S	Indirect	See footnote.
Common Stock	Disposition	2010-12-23	2,293	$8.09	0	No	4	S	Indirect	See footnote.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote.
No	4	S	Indirect	See footnote.
No	4	S	Indirect	See footnote.
No	4	S	Indirect	See footnote.
No	4	S	Indirect	See footnote.
No	4	S	Indirect	See footnote.
No	4	S	Indirect	See footnote.
No	4	S	Indirect	See footnote.
No	4	S	Indirect	See footnote.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1	Direct

Footnotes

Shares are held by Sofinnova Venture Partners VI, L.P. ("SV VI"). Sofinnova Management VI, L.L.C. ("SV VI LLC"), the general partner of SV VI, and Michael F. Powell, a director of the issuer, James I. Healy, Alain L. Azan and Eric P. Buatois, the managing members of SV VI LLC, may be deemed to share voting and dispositive power over the shares held by SV VI. Such persons and entities disclaim beneficial ownership of shares held by SV VI except to the extent of any pecuniary interest therein.
Shares held by Sofinnova Venture Partners VI GmbH & Co. KG. ("SV VI KG"). Sofinnova Management VI, L.L.C. ("SV VI LLC"), the managing limited partner of SV VI KG, and Michael F. Powell, a director of the issuer, James I. Healy, Alain L. Azan and Eric P. Buatois, the managing members of SV VI LLC, may be deemed to share voting and dispositive power over the shares held by SV VI KG. Such persons and entities disclaim beneficial ownership of shares held by SV VI KG except to the extent of any pecuniary interest therein.
Shares are held by Sofinnova Venture Affiliates VI, L.P. ("SV VI Affiliates"). Sofinnova Management VI, L.L.C. ("SV VI LLC"), the general partner of SV VI Affiliates, and Michael F. Powell, a director of the issuer, James I. Healy, Alain L. Azan and Eric P. Buatois, the managing members of SV VI LLC, may be deemed to share voting and dispositive power over the shares held by SV VI Affiliates. Such persons and entities disclaim beneficial ownership of shares held by SV VI Affiliates except to the extent of any pecuniary interest therein.